VIKTORIA-1 #ESMO26

In PIK3CA-mutated HR+/HER2− advanced #BreastCancer post-CDK4/6i, gedatolisib-based regimens improved PFS vs alpelisib + fulvestrant, with fewer treatment discontinuations due to adverse events (4–5% vs 19%).

@OncoAlert #bcsm @GustaveRoussy